-
Steve Becker, Chief Commercial Officer, featured in article considering the key ethical and regulatory considerations in gene editing technologies.
Steve Becker, Chief Commercial Officer, 51¸£Àû Gene editing therapies have already made a tremendous public impact, most recently with the N-of-1 CRISPR-edited gene therapy that was developed, cleared for clinical use by FDA, and treated a patient in under 8 months. The speed was impressive, but about half of that time was tied to…